SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
Por:
Torres I, Bellido-Blasco JB, Gimeno C, Burgos JS, Albert E, Moya-Malo R, Gascó-Laborda JC, Tornero A, Soriano J, Meseguer-Ferrer N, Martínez-Serrano M, Ortíz-Rambla J, Buj H, Hernández N, Peiró S, Salas D, Limón R, Vanaclocha H, Sánchez-Payá J, Díez-Domingo J, Comas I, González-Candelas F and Navarro D
Publicada:
1 ago 2022
Ahead of Print:
20 abr 2022
Resumen:
SARS-CoV-2 Delta variant breakthrough infections in nursing home residents following vaccination with Comirnaty® COVID-19 vaccine were characterized. In total, 201 participants (median age, 87 years; range, 64-100; 133 female) from two nursing homes in the Valencian community (Spain) were included. SARS-CoV-2-Spike (S) antibody responses were determined by a lateral flow immunocromatography (LFIC) assay and by quantitative electrochemiluminescent assay in LFIC-negative participants. SARS-CoV-2-S-IFN? T cells were enumerated by flow cytometry in 10 participants. Nasopharyngeal SARS-CoV-2 RNA loads were quantified by RT-PCR assays. Vaccine breakthrough COVID-19 due to the Delta variant occurred in 39 residents (median age, 87 years; range, 69-96; 31 female) at a median of 6.5 months after vaccination (9 requiring hospitalization). Breakthrough infections occurred at a higher rate (P<0.0001) in residents who had not been previously infected with SARS-CoV-2 (naïve) (33/108; 18%) than in those with prior diagnosis of SARS-CoV-2 infection (experienced) (6/93; 6.4%), and were more likely (P<0.0001) to develop in residents who tested negative by LFIC (20/49) at 3 months (3M) after vaccination as compared to their LFIC-positive counterparts (19/142). Among LFIC-negative residents, a trend towards lower plasma anti-RBD antibody levels were noticed in those developing breakthrough infection (P=0.16). SARS-CoV-2 RNA loads in nasopharyngeal specimens were lower in SARS-CoV-2-experienced residents (P<0.001) and in those testing positive by LFIC (P=0.13). Frequency of SARS-CoV-2-S-reactive T cells at 3 months was similar in LFIC-negative residents with (n=7) or without (n=3) breakthrough infection. Prior history of SARS-CoV-2 infection and detection of S-reactive antibodies by LFIC at 3 months are associated with a lower risk of Delta-variant breakthrough infection in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination. This article is protected by copyright. All rights reserved.
Filiaciones:
Torres I:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Bellido-Blasco JB:
Sección de Epidemiología, Centro de Salud Pública de Castellón, Valencia, Spain
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Valencia, Spain
Universitat Jaume I (UJI), Castelló, Spain
Gimeno C:
Microbiology Service, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
Burgos JS:
General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain
Albert E:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Moya-Malo R:
Centro de Salud Carinyena, Vila-Real, Castellón, Spain
Gascó-Laborda JC:
Sección de Epidemiología, Centro de Salud Pública de Castellón, Valencia, Spain
Tornero A:
Primary Health Directory, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Soriano J:
Primary Health Directory, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Meseguer-Ferrer N:
Sección de Epidemiología, Centro de Salud Pública de Castellón, Valencia, Spain
Martínez-Serrano M:
Microbiology Service, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Ortíz-Rambla J:
Unidad de Hospitalización Domiciliaria del Departamento de Salud de la Plana, Castellón, Spain
Buj H:
Laboratory Service, Hospital de la Plana, Vila-Real, Castellón, Spain
Hernández N:
Laboratory Service, Hospital de la Plana, Vila-Real, Castellón, Spain
Peiró S:
Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain
Salas D:
Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain
General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain
Limón R:
General Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain
Vanaclocha H:
General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain
:
Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain
Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain
Díez-Domingo J:
Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain
Comas I:
Biomedicine Institute of Valencia, Spanish Research Council (CSIC)
CIBER in Epidemiology and Public Health, Spain
González-Candelas F:
CIBER in Epidemiology and Public Health, Spain
Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain
Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain
Navarro D:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
Bronze
|